These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37827268)

  • 1. The efficiency of cabergoline vs pyridoxine for lactation inhibition-a randomized controlled trial.
    Dayan-Schwartz A; Yefet E; Massalha M; Hosari-Mhameed S; Remer-Gross C; Pasand E; Nachum Z
    Am J Obstet Gynecol; 2024 May; 230(5):561.e1-561.e8. PubMed ID: 37827268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition - A systematic review of clinical trials.
    Shrateh ON; Kumar KA; Jawed A; Shuja MH; Shamsi HUR; Naasan M
    J Gynecol Obstet Hum Reprod; 2024 Jun; 53(6):102783. PubMed ID: 38554942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition.
    BMJ; 1991 Jun; 302(6789):1367-71. PubMed ID: 1676318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial.
    Henkel A; Johnson SA; Reeves MF; Cahill EP; Blumenthal PD; Shaw KA
    Obstet Gynecol; 2023 Jun; 141(6):1115-1123. PubMed ID: 37486652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Cabergoline for Postpartum Lactation Inhibition or Suppression: A Systematic Review.
    Harris K; Murphy KE; Horn D; MacGilivray J; Yudin MH
    J Obstet Gynaecol Can; 2020 Mar; 42(3):308-315.e20. PubMed ID: 31285168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
    Rains CP; Bryson HM; Fitton A
    Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Breast Massage in Lactation for the Management of Engorgement, Plugged Ducts, and Mastitis.
    Witt AM; Bolman M; Kredit S; Vanic A
    J Hum Lact; 2016 Feb; 32(1):123-31. PubMed ID: 26644422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Cabergoline Safe and Effective for Postpartum Lactation Inhibition? A Systematic Review.
    Yang Y; Boucoiran I; Tulloch KJ; Poliquin V
    Int J Womens Health; 2020; 12():159-170. PubMed ID: 32210637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatments for breast engorgement during lactation.
    Mangesi L; Zakarija-Grkovic I
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD006946. PubMed ID: 27351423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral cabergoline. Single-dose inhibition of puerperal lactation.
    Caballero-Gordo A; Lopez-Nazareno N; Calderay M; Caballero JL; Mancheño E; Sghedoni D
    J Reprod Med; 1991 Oct; 36(10):717-21. PubMed ID: 1683403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of cabergoline for lactation inhibition in women living with HIV.
    Boucoiran I; Roy M; Poliquin V; Elwood C; Sheehan NL; Thibaudeau R; Ferreira E; Autmizguine J; Kakkar F; Boucher M; Money D; Tulloch K
    Int J STD AIDS; 2021 Jun; 32(7):654-661. PubMed ID: 33612017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
    Webster J
    Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabergoline: a new drug for the treatment of hyperprolactinaemia.
    Ferrari C; Piscitelli G; Crosignani PG
    Hum Reprod; 1995 Jul; 10(7):1647-52. PubMed ID: 8582955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case Study of Early Postpartum Excessive Breast Engorgement: Is it Related to Feedback Inhibition of Lactation?
    Coban A; Bayraktar S; Yıldız N; Tunçel D; Gökçay G; Ince Z
    J Hum Lact; 2021 May; 37(2):414-418. PubMed ID: 33030995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of feeding level, milking frequency, and single injection of cabergoline on feed intake, milk yield, milk leakage, and clinical udder characteristics during dry-off in dairy cows.
    Larsen M; Franchi GA; Herskin MS; Foldager L; Larsen MLV; Hernández-Castellano LE; Sørensen MT; Jensen MB
    J Dairy Sci; 2021 Oct; 104(10):11108-11125. PubMed ID: 34275624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatments for breast engorgement during lactation.
    Zakarija-Grkovic I; Stewart F
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD006946. PubMed ID: 32944940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery.
    Giorda G; de Vincentiis S; Motta T; Casazza S; Fadin M; D'Alberton A
    Gynecol Obstet Invest; 1991; 31(2):93-6. PubMed ID: 2037265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short communication: The effects of cabergoline administration at dry-off of lactating cows on udder engorgement, milk leakages, and lying behavior.
    Bach A; De-Prado A; Aris A
    J Dairy Sci; 2015 Oct; 98(10):7097-101. PubMed ID: 26277312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline.
    Melis GB; Mais V; Paoletti AM; Beneventi F; Gambacciani M; Fioretti P
    Obstet Gynecol; 1988 Mar; 71(3 Pt 1):311-4. PubMed ID: 3279351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine agonists for preventing ovarian hyperstimulation syndrome.
    Tang H; Mourad S; Zhai SD; Hart RJ
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008605. PubMed ID: 27901279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.